Skip To Main Content
Sudhesh Kumar on Muck Rack

Sudhesh Kumar

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sudhesh

Contact Sudhesh, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Older Age, STAG2 , and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents

|
By Momna Warraich, Sudhesh Kumar, Mahnoor Fatima
| Wiley Online Library Verified
1 Introduction AML is a heterogeneous disease characterized by a wide range of genomic alterations that impact clinical outcomes and offer potential targets for novel therapies [1]. In older or unfit patients who are ineligible for intensive chemotherapy, the combination of venetoclax with hypomethylating agent (Ven-HMA) has emerged as the standard frontline treatment [2].
Open in Who Shared Issue with article?

Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia

|
By Mahnoor Fatima, Sudhesh Kumar, Momna Warraich, Kristen B. McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Abhishek A. Mangaonkar, Antoine Saliba, Mark Litzow, William Hogan, Mithun V. Shah, Mrinal Patnaik, Animesh Pardanani, Talha Badar, James M. Foran, Jeanne Palmer, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat Verified
| Nature Verified
Venetoclax (Ven) in combination with hypomethylating agents (HMA) has become the standard frontline therapy for elderly or unfit patients with newly diagnosed acute myeloid leukemia (ND-AML). Despite impressive initial response rates demonstrated in the pivotal phase III VIALE-A trial, disease progression or relapse occurred in 42% of patients receiving Ven plus azacytidine [1].
Open in Who Shared Issue with article?

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast‐Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent

|
By Naseema Gangat Verified, Momna Warraich, Sudhesh Kumar
| Wiley Online Library Verified
Leukemic transformation arising in the context of a myeloproliferative neoplasm (MPN), namely primary myelofibrosis (PMF), polycythemia vera (PV) or essential thrombocythemia (ET), is referred to as “MPN blast-phase” (MPN-BP), and requires the presence of ≥ 20% circulating (CB) or bone marrow (BM) blasts, while 10%–19% blasts defines “accelerated phase” disease (MPN-AP) [1].
Open in Who Shared Issue with article?
See all 3 articles